Avetra, a Contract Research Organisation (CRO), announced on Tuesday that it is launching a modern, site-centric operating model aimed at realigning the relationship between sponsors, CROs, and investigative sites.

The company intends to deliver faster, clearer, and more predictable clinical trial execution with access to over 350 research-experienced sites and a fully integrated in-house central laboratory.

Avetra's model prioritises transparency in budgets and timelines; cash-flow-aligned support for investigative sites; faster, more predictable study startup; integrated lab and operational infrastructure; and clear, accountable communication with sponsors.

The company's network covers leading research sites across gastroenterology, endocrinology, ophthalmology, obesity, vaccines, and additional therapeutic areas. Its central laboratory division will further streamline specimen handling, logistics, and data turnaround.

Avetra is also preparing to start its first large-scale gastrointestinal programme in the third quarter of 2026.